No products in the cart.
#StudyGraphics: Concomitant chemoradiotherapy improves survival in elderly adults with locally advanced head and neck squamous cell carcinoma
Click to read this study in JAMA Network Open.
Tag: cetuximab
#VisualAbstract: Adagrasib provides antitumour activity against KRAS G12C mutant metastatic colorectal cancer both as monotherapy and in combination with cetuximab
Overall tumour response to monotherapy treatment with adagrasib was 23% 46% in combination with cetuximab. Median progression-free survival was 5.6 ...
#VisualAbstract: Pembrolizumab provides survival benefit in PD-L1 positive advanced head and neck cancer
1. Pembrolizumab-alone or pembrolizumab-chemotherapy prolonged overall survival vs cetuximab-chemotherapy in the PD-L1 positive population 2. While pembrolizumab-chemotherapy found an improved ...
#VisualAbstract: Chemoradiotherapy with carboplatin is more effective than cetuximab in head and neck squamous cell carcinoma
Click to read this study in JAMA Otolaryngology - Head & Neck Surgery.
#VisualAbstract: Pembrolizumab-based therapy is more effective with increasing PD-L1 expression in head and neck squamous cell carcinomas
Click to read this study in the Journal of Clinical Oncology.
#VisualAbstract: Induction chemotherapy with docetaxel, cisplatin, and cetuximab offers similar outcomes with a potentially more favorable treatment schedule than 5-fluorouracil
Click to read this study in the European Journal of Cancer.
#VisualAbstract: Docetaxel, cisplatin, and cetuximab regimen is a safe alternative for patients with squamous cell carcinoma of the head and neck
Click to read the study in The Lancet Oncology.
#VisualAbstract: Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
1. A phase 3 randomized clinical trial showed that combined therapy using a BRAF inhibitor (encorafenib), EGFR monoclonal antibody (cetuximab) ...
Combined Encorafenib-Binimetinib-Cetuximab therapy associated with longer overall survival in patients with BRAF V600E-mutated coloreactal cancer
1. A phase 3 randomized clinical trial showed that combined therapy using a BRAF inhibitor (encorafenib), EGFR monoclonal antibody (cetuximab) ...
Cetuximab and neoadjuvant chemotherapy may decrease survival in liver metastasis
Image: PD 1. The addition of cetuximab to chemotherapy before and after surgery decreases survival in colorectal cancer with resectable ...
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.